New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.

By Julie Steenhuysen CHICAGO, May 31 (Reuters) - Revolution Medicine's experimental pancreatic cancer pill doubled survival compared with chemotherapy and improved symptoms enough that some patients ...

Those taking daraxonrasib lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients.

The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.

Revolution Medicines Inc.’s experimental pancreatic cancer drug daraxonrasib delayed painful symptoms for months, in addition ...

Dedifferentiated liposarcoma (DDLS) is a rare and aggressive soft tissue cancer with few effective treatment options. But now a clinical trial led by doctors from Memorial Sloan K ...

Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic ...

Intraoperative cesium-131 tile-based radiation therapy (TBRT) with GammaTile significantly improved local control, surgical bed recurrence-free survival (SB-RFS), and overall surv ...

Previously, immature overall survival results of the NRG Oncology GY018 (NRG-GY018) trial suggested that the use of the immunotherapy drug pembrolizumab in combination with chemotherapy improved ...